Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essenti...
| Corporate Author: | SpringerLink (Online service) |
|---|---|
| Other Authors: | Yarden, Yosef (Editor, http://id.loc.gov/vocabulary/relators/edt), Elkabets, Moshe (Editor, http://id.loc.gov/vocabulary/relators/edt) |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Cham :
Springer International Publishing : Imprint: Springer,
2018.
|
| Edition: | 1st ed. 2018. |
| Series: | Resistance to Targeted Anti-Cancer Therapeutics,
15 |
| Subjects: | |
| Online Access: | Full Text via HEAL-Link |
Similar Items
-
Resistance to Targeted Therapies in Lymphomas
Published: (2019) -
Resistance to Tyrosine Kinase Inhibitors
Published: (2016) -
Targeting the DNA Damage Response for Anti-Cancer Therapy
Published: (2018) -
Resistance to Ibritumomab in Lymphoma
Published: (2018) -
Cancer Stem Cell Resistance to Targeted Therapy
Published: (2019)